These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

567 related articles for article (PubMed ID: 19476973)

  • 1. Shear-induced global thrombosis test of native blood: pivotal role of ADP allows monitoring of P2Y12 antagonist therapy.
    Saraf S; Wellsted D; Sharma S; Gorog DA
    Thromb Res; 2009 Sep; 124(4):447-51. PubMed ID: 19476973
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12(R) rapid analyzer: the VERIfy Thrombosis risk ASsessment (VERITAS) study.
    Malinin A; Pokov A; Spergling M; Defranco A; Schwartz K; Schwartz D; Mahmud E; Atar D; Serebruany V
    Thromb Res; 2007; 119(3):277-84. PubMed ID: 16563469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clopidogrel (Plavix) and cardiac surgical patients: implications for platelet function monitoring and postoperative bleeding.
    Tanaka KA; Szlam F; Kelly AB; Vega JD; Levy JH
    Platelets; 2004 Aug; 15(5):325-32. PubMed ID: 15370104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of VASP-phosphorylation assay to light-transmission aggregometry in assessing inhibition of the platelet ADP P2Y12 receptor.
    Pampuch A; Cerletti C; de Gaetano G
    Thromb Haemost; 2006 Dec; 96(6):767-73. PubMed ID: 17139371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validation of a VerifyNow-P2Y12 cartridge for monitoring platelet inhibition with clopidogrel.
    Malinin A; Pokov A; Swaim L; Kotob M; Serebruany V
    Methods Find Exp Clin Pharmacol; 2006 Jun; 28(5):315-22. PubMed ID: 16845449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of platelet response to clopidogrel with multiple electrode aggregometry, the VerifyNow P2Y12 analyzer and platelet Vasodilator-Stimulated Phosphoprotein flow cytometry.
    von Beckerath N; Sibbing D; Jawansky S; Braun S; Morath T; Vogt W; Schömig A; Kastrati A
    Blood Coagul Fibrinolysis; 2010 Jan; 21(1):46-52. PubMed ID: 19823079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. P2Y12, a new platelet ADP receptor, target of clopidogrel.
    Herbert JM; Savi P
    Semin Vasc Med; 2003 May; 3(2):113-22. PubMed ID: 15199474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Global Thrombosis Test (GTT) can detect major determinants of haemostasis including platelet reactivity, endogenous fibrinolytic and thrombin generating potential.
    Yamamoto J; Inoue N; Otsui K; Ishii H; Gorog DA
    Thromb Res; 2014 May; 133(5):919-26. PubMed ID: 24613697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clopidogrel attenuates coated-platelet production in patients undergoing elective coronary catheterization.
    Norgard NB; Saya S; Hann CL; Hennebry TA; Schechter E; Dale GL
    J Cardiovasc Pharmacol; 2008 Dec; 52(6):536-9. PubMed ID: 19034031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clopidogrel anti-platelet effect: an evaluation by optical aggregometry, impedance aggregometry, and the platelet function analyzer (PFA-100).
    Dyszkiewicz-Korpanty A; Olteanu H; Frenkel EP; Sarode R
    Platelets; 2007 Nov; 18(7):491-6. PubMed ID: 17852774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of ADP-induced platelet aggregation with light transmission aggregometry and multiple electrode platelet aggregometry before and after clopidogrel treatment.
    Sibbing D; Braun S; Jawansky S; Vogt W; Mehilli J; Schömig A; Kastrati A; von Beckerath N
    Thromb Haemost; 2008 Jan; 99(1):121-6. PubMed ID: 18217143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insights into the interpretation of light transmission aggregometry for evaluation of platelet aggregation inhibition by clopidogrel.
    Lordkipanidzé M; Pharand C; Palisaitis DA; Schampaert E; Diodati JG
    Thromb Res; 2009 Nov; 124(5):546-53. PubMed ID: 19419755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis.
    Sibbing D; Braun S; Morath T; Mehilli J; Vogt W; Schömig A; Kastrati A; von Beckerath N
    J Am Coll Cardiol; 2009 Mar; 53(10):849-56. PubMed ID: 19264241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the pharmacodynamic effects of the platelet ADP receptor antagonists clopidogrel and AR-C69931MX in patients with ischaemic heart disease.
    Storey RF; Wilcox RG; Heptinstall S
    Platelets; 2002 Nov; 13(7):407-13. PubMed ID: 12487788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiplatelet effect of clopidogrel in patients with aspirin therapy undergoing percutaneous coronary interventions--limited inhibition of the P2Y12 receptor.
    Lepäntalo A; Virtanen KS; Reséndiz JC; Mikkelsson J; Viiri LE; Karhunen PJ; Lassila R
    Thromb Res; 2009 Jun; 124(2):193-8. PubMed ID: 19232433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Retention Index Test Homburg (RTH-II): Response to clopidogrel and comparison with aggregometry and CD62P-expression.
    Klinkhardt U; Wenzel E; Harder S
    Platelets; 2006 Feb; 17(1):42-8. PubMed ID: 16308186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Platelet aggregometry and receptor binding to predict the magnitude of antithrombotic and bleeding time effects of clopidogrel in rabbits.
    Wong PC; Crain EJ; Watson CA; Jiang X; Hua J; Bostwick JS; Ogletree ML; Schumacher WA; Rehfuss R
    J Cardiovasc Pharmacol; 2007 May; 49(5):316-24. PubMed ID: 17513951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of the T744C polymorphism of the P2Y12 gene on platelet response to a 600-mg loading dose of clopidogrel in 597 patients with non-ST-segment elevation acute coronary syndrome.
    Cuisset T; Frere C; Quilici J; Morange PE; Saut N; Lambert M; Camoin L; Vague IJ; Bonnet JL; Alessi MC
    Thromb Res; 2007; 120(6):893-9. PubMed ID: 17337040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of clopidogrel responsiveness: measurements of maximum platelet aggregation, final platelet aggregation and their correlation with vasodilator-stimulated phosphoprotein in resistant patients.
    Gurbel PA; Bliden KP; Etherington A; Tantry US
    Thromb Res; 2007; 121(1):107-15. PubMed ID: 17400283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transitioning patients from cangrelor to clopidogrel: pharmacodynamic evidence of a competitive effect.
    Steinhubl SR; Oh JJ; Oestreich JH; Ferraris S; Charnigo R; Akers WS
    Thromb Res; 2008; 121(4):527-34. PubMed ID: 17631948
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.